SCHEMBL3451280

SCHEMBL3451280

Clc1nccc(NC2CCCC2)n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSK P43235 3/20 0.58
ALDH1A1 P00352 2/20 0.50
KDM4E B2RXH2 2/20 0.50
MALT1 Q9UDY8 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
KMT2A Q03164 3/20 0.47
HRH3 Q9Y5N1 2/20 0.47
MEN1 O00255 2/20 0.47
KMT5B Q4FZB7 2/20 0.45
KMT5C Q86Y97 2/20 0.45
USP2 O75604 1/20 0.45
TP53 P04637 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
ALOX15 P16050 1/20 0.45
HSD17B10 Q99714 1/20 0.45
AURKB Q96GD4 2/20 0.45
MAP4K4 O95819 1/20 0.44
CDC7 O00311 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19174443 0.98 CTSK (0.60) CTSKALDH1A1KDM4EMALT1L3MBTL1
SCHEMBL27819587 0.96 CTSK (0.54) CTSKALDH1A1KDM4EMALT1L3MBTL1
SCHEMBL17544472 0.93 MALT1 (0.57) CTSKALDH1A1KDM4EMALT1L3MBTL1
SCHEMBL3807631 0.85 MALT1 (0.50) CTSKALDH1A1MALT1KMT2AHRH3
SCHEMBL12526894 0.85 HRH3 (0.68) CTSKALDH1A1MALT1KMT2AHRH3
SCHEMBL31135484 0.85 MERTK (0.54) CTSKALDH1A1MALT1KMT2AHRH3
SCHEMBL13213387 0.85 MALT1 (0.50) CTSKALDH1A1MALT1KMT2AHRH3
SCHEMBL19462069 0.85 MAPK1 (0.49) CTSKALDH1A1MALT1KMT2AHRH3
SCHEMBL26179070 0.83 MALT1 (0.45) CTSKALDH1A1KDM4EMALT1L3MBTL1
Hydrochloric Acid SCHEMBL1748490 0.83 HRH3 (0.66) CTSKALDH1A1MALT1KMT2AHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111423437-B Preparation method of palbociclib intermediate 天津法莫西医药科技有限公司 2021-02-26 CN claimed
CN-111423437-A Preparation method of palbociclib intermediate 天津法莫西医药科技有限公司 2020-07-17 CN claimed
CN-111423437-B Preparation method of palbociclib intermediate 天津法莫西医药科技有限公司 2021-02-26 CN disclosed
CN-111423437-A Preparation method of palbociclib intermediate 天津法莫西医药科技有限公司 2020-07-17 CN disclosed
CN-102203070-A Alkoxy-and alkylthio-substituted anilinopyrimidines BAYER CROPSCIENCE AG 2011-09-28 CN disclosed
US-7820704-B2 Substituted heteroaryl derivatives, compositions, and methods of use TRANSTECH PHARMA, INC. (US) 2010-10-26 US disclosed
CN-1946703-A Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators TRANSTECH PHARMA INC (US) 2007-04-11 CN disclosed
EP-1753735-A1 SUBSTITUTED THIAZOLE AND PYRIMIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR MODULATORS Transtech Pharma, Inc. (US) 2007-02-21 EP disclosed
US-20050261294-A1 Substituted heteroaryl derivatives, compositions, and methods of use VTVX HOLDINGS I LLC 2005-11-24 US disclosed
WO-2005103022-A1 SUBSTITUTED THIAZOLE AND PYRIMIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR MODULATORS TRANSTECH PHARMA, INC. (US) 2005-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261294-A1 Substituted heteroaryl derivatives, compositions, and methods of use MC5R, MC3R, MC4R CTSK 2740/4885ALDH1A1 1513/4885KDM4E 2378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.